aTYR PHARMA INC
No SEC Form 4 filings for $ATYR in the last 30 days.
See all $ATYR insider activity →Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
aTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
Over the past 7 days, alphai's AI scored 1 news story mentioning ATYR (aTYR PHARMA INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ATYR coverage spans financial news, corporate actions and market movers.
Regulatory timeline update provides clarity for upcoming trial.
New CFO appointment may affect financial strategy and investor perception.
A large cost-cutting move can extend runway and refocus resources, but it also increases perceived execution and risk.
The restructuring and FDA protocol-feedback timeline are near-term catalysts for ATYR’s cash burn expectations and Phase 3 execution risk.
Termination shifts development and commercialization rights for the Reversion Product (efzofitimod) toward aTyr, with regulatory and data handover mechanics.
alphai scores every news story that mentions ATYR with an AI model for sentiment and relevance, and aggregates insider trades from aTYR PHARMA INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
2 min readaTyr (LIFE) appointed Brandon Yaras as CFO. City Therapeutics, Cue Biopharma (CUE), Longeveron (LGVN), Olema Oncology (OLEM), and Stuart Therapeutics made CFO appointments. Sanofi (SNY) expanded its CFO's role to include business operations and M&A.
3 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD Company awaiting comments f
4 min readaTYR PHARMA INC (ATYR) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Exhibit 99.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (this “ Agreement ”) is made and entered into as of July 30, 2026 (“ Execution Date ”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of business at 10240 Sorrento Valley Road, Su
6 min readSCHIMMEL PAUL purchased 100,000 indirectly-held shares of aTYR PHARMA INC (ATYR) at $0.50 on 2026-05-27.
2 min readThis article provides a detailed financial overview of Atyr Pharma Inc (ATYR), including its income statement, balance sheet, and cash flow statement, along with key financial ratios. It highlights the company's financial health signals, annual and quarterly metrics, and frequently asked questions about its performance. The analysis indicates weak overall financial health with low profitability and negative cash flow, despite strong liquidity and low leverage.
3 min readSAN FRANCISCO, Nov. 27, 2025 ( GLOBE NEWSWIRE ) -- Global plaintiffs' rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. ( NASDAQ:ATYR ) .
2 min readLOS ANGELES, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
3 min readNEW YORK, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. ( NASDAQ:ATYR ) , Marex Group PLC ( NASDAQ:MRX ) , Cepton, Inc. ...
2 min read
